Bright Green Corporation Merges with PharmAGRI Capital Partners; Lynn Stockwell Appointed CEO and Chairwoman
Bright Green Corporation (OTC: BGXX) has announced a transformative merger with PharmAGRI Capital Partners, appointing Lynn Stockwell as CEO and Chairwoman. The merger consolidates BGXX's DEA registrations and other assets under a court-supervised restructuring plan.
Key developments include a strategic partnership with Tesla to deploy 10,000 Optimus 3+ humanoid robots across operations, and plans for four Nasdaq-listed SPACs through Drugs Made In America Acquisition Corps. PharmAGRI's "seed to syringe" model aims to restore U.S. pharmaceutical manufacturing sovereignty.
The company plans to file an S-1 registration statement and complete its IPO before year-end 2025, including a proposed reverse stock split and preferred share issuance pending court and FINRA approval.
Bright Green Corporation (OTC: BGXX) ha annunciato una fusione trasformativa con PharmAGRI Capital Partners, nominando Lynn Stockwell come CEO e Presidente. La fusione consolida le registrazioni DEA di BGXX e altri asset in un piano di ristrutturazione supervisionato dal tribunale.
Gli sviluppi chiave includono una partnership strategica con Tesla per dispiegare 10.000 robot umanoidi Optimus 3+ nelle operazioni, e piani per quattro SPAC quotate sul Nasdaq tramite Drugs Made In America Acquisition Corps. Il modello di PharmAGRI, “seed to syringe”, mira a ripristinare la sovranità della produzione farmaceutica negli Stati Uniti.
La società intende presentare una dichiarazione di registrazione S-1 e completare l’IPO entro la fine del 2025, inclusa una prevista reverse stock split e l’emissione di azioni privilegiate in attesa dell’approvazione del tribunale e della FINRA.
Bright Green Corporation (OTC: BGXX) ha anunciado una fusión transformadora con PharmAGRI Capital Partners, designando a Lynn Stockwell como CEO y Presidenta del Consejo. La fusión consolida las registraciones DEA de BGXX y otros activos bajo un plan de reestructuración supervisado por un tribunal.
Entre los avances clave se encuentra una asociación estratégica con Tesla para desplegar 10,000 robots humanoides Optimus 3+ en las operaciones, y planes para cuatro SPACs cotizadas en Nasdaq a través de Drugs Made In America Acquisition Corps. El modelo de PharmAGRI, “seed to syringe”, busca restablecer la soberanía de la fabricación farmacéutica en Estados Unidos.
La empresa planea presentar una declaración de registro S-1 y completar su IPO antes de finales de 2025, incluida una posible división inversa de acciones y la emisión de acciones preferentes pendiente de la aprobación del tribunal y de FINRA.
Bright Green Corporation (OTC: BGXX)는 PharmAGRI Capital Partners와의 혁신적 합병을 발표했으며, Lynn Stockwell를 CEO 겸 회장으로 임명했습니다. 이 합병은 BGXX의 DEA 등록 및 기타 자산을 법원의 감독 하에 진행되는 구조조정 계획으로 통합합니다.
주요 발전으로는 Tesla와의 전략적 파트너십을 통해 운영 전반에 걸쳐 10,000대의 Optimus 3+ 휴머노이드를 배치하고, Drugs Made In America Acquisition Corps를 통해 Nasdaq에 상장된 네 개의 SPAC를 추진하는 것이 포함됩니다. PharmAGRI의 “seed to syringe” 모델은 미국 제약 제조주권의 회복을 목표로 합니다.
회사는 S-1 등록서를 제출하고 2025년 말 이전에 IPO를 완료하는 것을 계획하고 있으며, 법원 및 FINRA의 승인을 기다리며 주식 대체 분할과 우선주 발행을 포함합니다.
Bright Green Corporation (OTC: BGXX) a annoncé une fusion transformatrice avec PharmAGRI Capital Partners, en nommant Lynn Stockwell au poste de PDG et de Présidente. La fusion consolide les enregistrements DEA de BGXX et d’autres actifs dans le cadre d’un plan de restructuration supervisé par un tribunal.
Parmi les développements clés figurent un partenariat stratégique avec Tesla pour déployer 10 000 robots humanoïdes Optimus 3+ dans les opérations, et des plans pour quatre SPACs cotés au Nasdaq via Drugs Made In America Acquisition Corps. Le modèle “seed to syringe” de PharmAGRI vise à restaurer la souveraineté de la fabrication pharmaceutique américaine.
L’entreprise prévoit de déposer une déclaration d’enregistrement S-1 et de finaliser son IPO avant la fin de 2025, incluant une éventuelle scission inverse et l’émission d’actions préférentielles en attendant l’approbation du tribunal et de la FINRA.
Bright Green Corporation (OTC: BGXX) hat eine transformative Fusion mit PharmAGRI Capital Partners angekündigt und Lynn Stockwell zum CEO und Vorsitzenden des Vorstands ernannt. Die Fusion konsolidiert BGXXs DEA-Registrierungen und andere Vermögenswerte unter einem gerichtlich beaufsichtigten Restrukturierungsplan.
Zu den wichtigsten Entwicklungen gehört eine strategische Partnerschaft mit Tesla zur Bereitstellung von 10.000 Optimus 3+ Humanoiden in den Betrieben, sowie Pläne für vier an der Nasdaq notierte SPACs über Drugs Made In America Acquisition Corps. PharmAGRIs „seed to syringe“-Modell zielt darauf ab, die Souveränität der pharmaceutischen Fertigung in den USA wiederherzustellen.
Das Unternehmen plant, eine S-1-Registrierung einzureichen und vor Ende 2025 seinen IPO abzuschließen, einschließlich einer vorgeschlagenen Umkehrsplit und Ausgabe von Vorzugsaktien, vorbehaltlich der Zustimmung durch das Gericht und FINRA.
Bright Green Corporation (OTC: BGXX) أعلنت عن اندماج تحويلي مع PharmAGRI Capital Partners، وتعيين لين ستوكويل كمدير تنفيذي ورئيسة للمجلس. يدمج الدمج تسجيلات DEA الخاصة بـ BGXX وأصول أخرى ضمن خطة إعادة هيكلة بإشراف المحكمة.
تشمل التطورات الرئيسية شراكة استراتيجية مع Tesla لنشر 10,000 روبوت بشري Optimus 3+ عبر العمليات، وخطط لأربع شركات SPAC مدرجة في ناسداك من خلال Drugs Made In America Acquisition Corps. نموذج PharmAGRI من “الزرع إلى الحقنة” يهدف إلى استعادة سيادة التصنيع الدوائي في الولايات المتحدة.
تخطط الشركة لتقديم بيان تسجيل S-1 وإكمال اكتتابها العام الأولي قبل نهاية عام 2025، بما في ذلك تقسيم عكسي مقترح و إصدار أسهم مميزة رهن موافقة المحكمة وFINRA.
Bright Green Corporation (OTC: BGXX) 已宣布与 PharmAGRI Capital Partners 的具有变革性的合并，任命 Lynn Stockwell 为首席执行官兼董事会主席。此次合并将 BGXX 的 DEA 注册及其他资产纳入法院监督下的重组计划中。
主要进展包括与 Tesla 的战略伙伴关系，计划在运营中部署 10,000 台 Optimus 3+ 人形机器人，并通过 Drugs Made In America Acquisition Corps 推出四家在纳斯达克上市的 SPAC。PharmAGRI 的“种子到注射器”模式旨在恢复美国药品制造的主权。
公司计划提出 S-1 注册声明，并在 2025 年底前完成首次公开发行（IPO），包括拟议的股票分拆及优先股发行，需法院与 FINRA 的批准。
- Strategic partnership with Tesla for 10,000 Optimus 3+ robots to enhance operational efficiency
- Vertical integration through 'seed to syringe' manufacturing model on American soil
- Four planned Nasdaq-listed SPACs to expand platform reach
- Consolidation of DEA registrations and Board of Pharmacy licensure
- Planned IPO by year-end 2025 to strengthen market position
- Court-supervised restructuring indicates financial distress
- Reverse stock split and share issuance may lead to dilution
- Significant capital requirements for robotic deployment and infrastructure
- Regulatory uncertainties pending SEC, FINRA, and court approvals
Insights
Bright Green's merger with PharmAGRI fundamentally transforms the company with new leadership, Tesla robotics partnership, and pharmaceutical sovereignty focus.
The merger between Bright Green Corporation (BGXX) and PharmAGRI Capital Partners represents a complete strategic overhaul of the company under court-supervised restructuring. Lynn Stockwell's appointment as CEO and Chairwoman centralizes control, as she'll appoint directors from her Drugs Made In America Acquisition Corps, a series of Nasdaq SPACs targeting DEA-licensed pharmaceutical businesses.
The transaction consolidates BGXX's regulatory assets - including DEA registrations and Board of Pharmacy licensure - into PharmAGRI's "seed to syringe" pharmaceutical infrastructure platform. This vertical integration strategy aims to capture federal contracts while supporting EB-5 investor pathways and controlled substance exports.
The Tesla partnership is particularly significant, with plans to deploy up to 10,000 Optimus 3+ humanoid robots across operations. This automation strategy targets both compliance requirements and labor economics - eliminating low-wage positions while creating high-wage technical roles that align with federal compliance and sovereign employment objectives.
Financially, the company plans several key steps: filing an S-1 registration with the SEC, completing a reverse stock split, issuing preferred shares (pending court and FINRA approval), and targeting a Nasdaq relisting with IPO completion before year-end 2025. These steps position PharmAGRI for market access and potential M&A activity to consolidate pharmaceutical production assets.
The merger fundamentally transforms BGXX from its previous business model into a federally-aligned pharmaceutical infrastructure company with a focus on domestic production sovereignty - a significant pivot that completely redefines the company's market position, regulatory approach, and growth strategy.
Tesla Robotics to Power Sovereign “Seed to Syringe” Pharmaceutical Infrastructure
Fort Lauderdale, FL, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC: BGXX) has announced its merger with PharmAGRI Capital Partners, a federally aligned pharmaceutical infrastructure platform architected to restore U.S. drug manufacturing sovereignty. The transaction consolidates BGXX’s DEA registrations, Board of Pharmacy licensure, audited financials, and Nasdaq history into PharmAGRI under a court-supervised restructuring plan filed in the District of New Mexico.
Effective immediately, Lynn Stockwell has been appointed Chief Executive Officer and Chairwoman of PharmAGRI. Ms. Stockwell will appoint a new board composed of directors from her Drugs Made In America Acquisition Corps—a series of four Nasdaq-listed special purpose acquisition companies (SPACs) formed to acquire DEA-licensed and FDA-compliant pharmaceutical businesses. Acquisition Corps I has completed an IPO and II is completing the SEC review, with Corps III and IV in formation to expand the platform’s reach and consolidate sovereign production assets.
PharmAGRI’s vertically integrated model executes “seed to syringe” drug manufacturing entirely on American soil, supporting EB-5 investor pathways, federal contract capture, and export of U.S.-manufactured controlled substances. As part of the merger, PharmAGRI will assume control of Bright Green LLC, a USCIS- EB-5 Regional Center applicant. The Regional Center will undergo a strategic realignment to support sovereign pharmaceutical infrastructure, robotics deployment, and high-wage job creation consistent with EB-5 program requirements.
PharmAGRI has executed a Letter of Intent (LOI) with Tesla to deploy up to 10,000 Optimus 3+ humanoid robotics across its owner-operator farm operations, API synthesis, and prescription drug manufacturing. The deployment is engineered for diversion control and DEA labor compliance, eliminating low-wage repetitive tasks and elevating the substantially reduced labor force into high-wage technical roles. It also ensures no reliance on undocumented labor, replacing historically exploited roles with robotics and retraining programs that support sovereign employment and wage elevation. The robotic are designed to meet all DEA and FDA compliance and are audit ready around-the-clock independently generating reports on global inventory, including standard operating procedures at any of the work stations.
Ms. Stockwell commented on the strategic vision behind the merger and Tesla partnership:
"We have a bold vision and a highly capable team committed to on-shoring this critical segment of the pharmaceutical industry. Through decisive commitments and disciplined execution, we’ve opened the door to a future powered by Tesla—securing procurement and deployment of Optimus 3+ robotics and advanced technologies that streamline our operational blueprint. This initiative not only elevates wages and reinforces lawful immigration practices, but establishes a sovereign infrastructure positioned to earn federal contracts and deliver strong returns to shareholders with conviction, and capability to secure the U.S. supply chain in the interest of all Americans."
PharmAGRI will soon file a Form S-1 registration statement with the U.S. Securities and Exchange Commission (SEC) and will comply with all Financial Industry Regulatory Authority (FINRA) requirements prior to its Nasdaq relisting. The proposed reverse stock split and preferred share issuance remain subject to final court and FINRA approval, after which Lynn Stockwell will become the majority shareholder of the combined company, consolidating governance and capital control to execute the platform’s sovereign pharmaceutical mission.
The company intends to complete its initial public offering (IPO) before year-end 2025, positioning PharmAGRI for full market access, federal contract execution, and strategic expansion across U.S. pharmaceutical infrastructure—while strengthening its mergers and acquisitions strategy to grow the revenue base and consolidate sovereign production assets.
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management as of such date. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” “shall” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. Such forward looking statements include, but are not limited to, the ability of the Company to implement the Plan and raise funds under the Company’s EB-5 program, the impact that new officers, directors and employees may have on the Company and the Company’s business and results of operations. The Company’s actual results could differ materially from those stated or implied
Media Contact:
Info@brightgreen.us
954-870-3099
FAQ
What is the strategic significance of Bright Green's merger with PharmAGRI Capital Partners?
How will Tesla's robotics partnership impact BGXX's operations?
Who is Lynn Stockwell and what is her role in the merged company?
What are BGXX's plans for going public after the merger?
How many SPACs is PharmAGRI planning to launch?
